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Abstract
Background: Dermatofibrosarcoma protuberans (DFSP) is a relatively common soft-tissue tumor. A more
aggressive appearing fibrosarcoma may arise in DFSP, changing its biological behavior. CD34 and apolipoprotein-D
are highly expressed in DFSP, but their prognostic significance is uncertain.
Methods: DFSP and fibrosarcomatous-DFSP (FS-DFSP) patients referred to our institute between 1982 and 2009
were identified. Fibrosarcomatous changes, expression of CD34 and apolipoprotein-D were evaluated.
Results: 40 patients, (median age 43 years, 55% males) were identified. Tumor was located in the limbs in 60%, in
the trunk in 40%. Thirty-seven patients had localized and 3 had metastatic disease. Thirteen (32%) patients were FS-
DFSP. All but one underwent surgery with adequate surgical margins in 72%. 7 FS-DFSP received also radiotherapy
(RT). Chemotherapy was administered to 3 patients with FS-DFSP. With a median follow-up of 49 months, the 5-OS
was 90%. Local recurrence rate was 23%: 42% FS-DFSP, 15% DFSP. Metastases developed in three FS-DFSP patients.
The 5-year EFS was 70% in localized patients. Histology (DFSP 75% vs. FS-DFSP 52%, p = 0.002), surgical margins
(adequate 74% vs. inadequate 55%, p = 0.02), site (limb 47% vs. trunk 100%), CD34 expression (CD34 positive: 70%
vs. CD34 negative: 33%, p = 0.05), and apolipoprotein-D expression (Apo-D positive: 73% vs. Apo-D negative: 33%,
p = 0.02) influenced the 5-year EFS, whereas sex, use of RT or number of previous surgical treatments did not.
Conclusions: Patients with DFSP have a high survival probability. Site, adequate surgical margins, presence of the
fibrosarcomatous component, lack of CD34 expression and apolipoprotein-D influence outcome.
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Background
Dermatofibrosarcoma protuberans (DFSP) is a low grade
malignant mesenchymal tumor that typically arises in
the dermis of the trunk and proximal extremities [1].
DFSP represents 1 to 6% of all soft tissue sarcomas
(STS) [2,3] and its frequency of detection slowly has
increased over time [4]. DFSP is characterized by latency
of initial diagnosis, slow infiltrative growth and a high
rate of local recurrence if not adequately treated. Death
due to metastatic disease is very rare (< 5%) [5]. Histolo-
gically, DFSP is usually characterized by uniform spindle
shaped cells with elongated neuroid nuclei, proliferating
in a storiform growth pattern, infiltrating subcutaneous
tissues with a “honeycomb” appearance. In rare cases
DFSP shows areas with high-grade fibrosarcomatous
changes (more than 5 mitoses/10 HPF, a fascicular
growth pattern, increased cellularity and atypia). When
dedifferentiated areas represent more than 5% of tumor
tissue, the lesion is classified as fibrosarcomatous ("high-
grade”) dermatofibrosarcoma protuberans (FS-DFSP)
[1]. The prognostic influence of the fibrosarcomatous
component of FS-DFSP has been debated [1].
Immunohistochemically, most DFSP stain positively
for CD34, whereas, FS-DFSP are CD34 positive in about
half of cases [6]. Apolipoprotein-D (Apo-D), a glycopro-
tein component of human plasma lipid transport system,
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arrays [7] and it has been proposed as a novel marker
for this neoplasm [8]. The role of Apo-D in DFSP is
unknown.
Most DFSPs are cured by wide surgical excision [1]. In
some experienced centers, Mohs micrographic surgery
(MMS) is routinely used instead of wide excision [5].
Radiotherapy also has been employed [9]. Chemotherapy
has been adopted in FS-DFSP patients. Distant metas-
tases generally occur as late sequela following repeated
local recurrences. In some of these patients, imatinib
has been used successfully [10,11]. The target of imati-
nib in these tumors is the product of a chromosomal
translocation that involves chromosomes 17 and 22,
resulting in fusion of the collagen type I aI( COL1A1)
and platelet-derived growth factor ß (PDGFß) gene, in
both DFSP and FS-DFSP [12]. A FISH probe for
COL1A1/PDGFB detection is not yet commercially
available.
The objective of this study was to retrospectively
examine all DFSP and FS-DFSP patients treated at our
institution in order to identify tumor- and treatment-
related factors influencing survival.
Methods
After obtaining Institutional Review Board approval, all
patients diagnosed with DFSP and FS-DFSP between
1982-2009 were identified from the database of the
Pathology Department of Musculoskeletal Oncology at
the Rizzoli Institute. Two pathologists (M.G. and G.S.)
reviewed the slides. Tumors were classified according to
the Enzinger & Weiss criteria: FS-DFSP were identified
by the presence of fibrosarcomatous changes (more than
5m i t o s e s / 1 0H P F ,a“fascicular” growth pattern,
increased cellularity and atypia) in at least more than
5% of tumor tissue [1]. Immunohistochemical expres-
sion of CD34 (Qbend-10, 1-100 dilution, Dako, Carpin-
teria CA, USA) and Apo-D (36C6, 1-200 dilution,
Novocastra, New-castle-on-Tyne, UK) were assessed by
two pathologists (M-G. and L.Z.) in all patients with
adequate tumor tissue. Detection of the two antibodies
was performed on a Dako automated immunostainer
with universal detection kit streptavidin biotin-alkaline
phosphatase/red/detection system Dako after heat (Apo-
D) and enzyme (CD34) induced antigen retrieval.
All patients surgically treated at our institution with
histological diagnosis confirmed were included in the
analysis. After 1986, the staging consisted of a computed
tomography scan (CT-scan) and/or magnetic resonance
imaging of the primary lesion, and a chest CT-scan;
other specific tests (bone scan, abdomen CT-scan) were
performed only in the case of clinical suspicion. Prior to
1986, a plain chest X-ray and ultrasound of the lesion
were performed. Assessment of the surgical margins was
based on both the pathology report and the description
of the surgical excision. All patients were followed-up
with ultrasound, computer tomography or magnetic
resonance imaging studies at three to four-months inter-
vals for at least two years, and subsequently at six-
months intervals for another three years.
Pattern of recurrence for localized patients were
defined as follow: local recurrence, when tumor relapse
was confined to the primary tumor area; metastases, for
distant only metastases: local recurrence plus metastases
for local and distant recurrence.
Statistical Analysis
The following parameters were examined for prognostic
value in patients with localized disease: patient sex,
tumor anatomic site, surgical margins, histology, CD34
and Apo-D expression, number of previous surgical
treatment, use of radiotherapy.
The following categories were compared: tumor site
(extremity: at or distal to the shoulder joint and in the
groin or leg; trunk: proximal to the shoulder joint and
the groin); surgical margins (adequate: wide or radical;
inadequate: intralesional, marginal or contaminated mar-
gins, according to Enneking’s classification)[13]; histol-
ogy (DFSP vs. FS-DFSP); CD34 and Apo-D expression
(positive or negative), number of previous operations (0
or ≥ 1); adjuvant treatments (radiotherapy performed
within 3 months after tumor excision).
We analyzed overall survival (OS) and event-free sur-
vival (EFS). OS time was calculated from the time of
admission at our Institute to death or last follow-up
visit. EFS time was calculated from the time of admis-
sion at our Institute and the occurrence of an event. An
event was defined as local recurrence, distant recurrence
or death (disease-related or unrelated). All time-to-event
end points were modeled using the method of Kaplan
and Meier and analyzed by the log-rank test. The results
of the Cox model analysis are reported as relative risks
(RRs) and 95% confidence intervals (CIs).
Results
A total of 51 consecutive patients with histologic diag-
nosis of DFSP or FS-DFSP made between 1982 and
2009 were identified. Eleven patient were consultation
cases, therefore 40 patients were included in the study
(Table 1). Reason for admission at our institution was: a
new diagnosis in 4 patients (10%), local recurrence in 19
(47.5%), scar re-excision 14 (35%) and distant (lymph
node) metastases plus local recurrence in 3 patients
(7.5%). In 13 (32.5%) patients, sarcomatous changes
were documented. In 26 of the 40 evaluable patients
tissue samples were available for immunohistochemical
assessment of the expression of CD34+ and Apo-D
(Figure 1, Table 2).
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Most patients (36/40) had already been surgically trea-
ted. Thirty-nine patients (97.5%) underwent surgery at
our Institute. The amputation rate was 8% (3/39). One
patient refused the planned surgical treatment (amputa-
tion) and was lost to follow-up. Adequate surgical mar-
gins were detected in 28 of 39 (72%) surgically treated
patients (Table 1). Radiotherapy was administered to 11
patients ***(7 with FS-DFSP).
Chemotherapy
Adjuvant ifosfamide and epirubicin was administered to
3 patients, all had FS-DFSP. In two cases it was
employed after excision of a local recurrence and in one
case following an amputation for local recurrence and
nodal metastases.
Outcome
Two patients were lost to follow-up. With a median fol-
low-up of 49 months (9-184), the 5-year overall survival
(OS) was 90% (95%CI 80-100) (Figure 2). The 5-year
event-free survival (EFS) was 69% (95%CI 51-87) in
localized patients. Histology (DFSP 75% (95%CI 53-97)
vs. FS-DFSP 52%,(95%CI 21-83), p = 0.002), surgical
margins (adequate 75% (95%CI 55-95) vs. inadequate
55% (95%CI 16-95), p = 0.02), site (extremity 47% (95%
CI 22-73) vs. trunk 100%, p = 0.005), influenced the
5-year EFS, whereas sex, use of RT or number of pre-
vious surgical treatments did not (Figure 3). Multivariate
analysis (via Cox regression) was performed. Site (extre-
mity RR 36.9, 95%CI 2.1 to 621.7, p = 0.01), sex (female
RR 0.08, 95%CI 0.009 to 0.7, p = 0.02) and histology
(FS-DFSP RR 0.1, 95%CI 0.01 to 0.8, p = 0.03) indepen-
dently influenced EFS.
CD34 and apolipoprotein-D expression
CD34 and Apo-D expression in DFSP and FS-DFSP is
shown in Table 2. The 5-year EFS was 70% (95%CI 43-
96) in CD34 positive vs. 33% (95%CI 0-71) in CD34
negative patients, (p = 0.05), and 73% (95%CI 45-100) in
Apo-D positive vs. 33% (95%CI 0-69) in Apo-D negative
p a t i e n t s ,( p=0 . 0 2 )( F i g u r e4 ) .W ed i dn o tf i n ds i g n i f i -
cant difference according to histology, site or margins
between the two groups. When CD34 and Apo-D were
included in the multivariate analysis they lost their prog-
nostic significance.
Pattern of failure in patients with localized disease
Incidence of local recurrence was 23% (9/39) overall:
42% in FS-DFSP and 15% in DFSP. All relapses occurred
in tumors of the limbs, while no recurrences were
observed in tumors of the trunk. Three patients with
local recurrence developed also pulmonary metastases;
all of them presented with FS-DFSP histology; none of
the patients with DFSP developed metastases. Local
recurrence occurred in 5/28 (18%) patients with ade-
quate margins and in 4/11 (36%) patients with inade-
quate (intralesional or marginal) margins. None of
patients with inadequate margins developed distant
metastases.
Discussion
DFSP is a soft tissue malignancy that often shows exten-
sive local invasion but rarely metastasizes [14]. DFSP
can lead to significant morbidity from repeated surgical
excisions, but infrequently leads to death [3,5,6,15,16].
Dermatofibrosarcoma protuberans with fibrosarcoma-
tous dedifferentiation (FS-DFSP) represents an more
aggressive appearing variant of DFSP, in which the prog-
nostic influence of the fibrosarcomatous component is
still debated. In our series the high grade variant repre-
sented almost a third of the cases, most likely due to a
referral center selection bias.
Table 1 Distribution of Clinical Pathologic, and
Treatment Characteristics
Number of patients identified 40
Sex
Female 18 (45%)
Male 22 (55%)
Site of primary
Limbs 24 (60%)
Trunk 16 (40%)
Age
Median (min-max) 39 yrs (4-80)
Histology
DFSP 27 (67.5%)
FS-DFSP 13 (32.5%)
Metastases at presentation
None 37 (92.5%)
Limphonodal 3 (7.5%)
Previous surgical treatment
Yes 36 (90%)
No 4 (10%)
Median n° of operations (min-max) 1 (1-5)
Margins *
Wide 28 (72%)
Marginal 5 (13%)
Intralesional 6 (15%)
Radiotherapy
Yes 11 (27%)
No 29 (73%)
Chemotherapy
Yes 3 (7.5%)
No 37 (92.5%)
* margins were available in the 39 patients surgically treated
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recurrence in 23% and local recurrence in 42%, while
DFSP was associated with a 15% of local recurrence rate
and no distant metastases. In other series the rates of
local and distant recurrence are similar (Table 3)
[6,15-18].
Furthermore the presence of high grade fibrosarcoma-
tous changes in our series is statistically associated with
inferior EFS. Therefore, fibrosarcomatous changes in
DFSP represent a clinically relevant form of tumor pro-
gression. Several authors suggested that fibrosarcomatous
areas within DFSP are associated with higher local recur-
rence and distant metastases rate [6,18-21]; however, in
these studies, the status of surgical margins was not clear.
Goldblum studied 18 FS-DFSP patients with adequate
margins and reported a relatively low local recurrence
rate (22%) (Table 3) and no distant recurrence. [19]. In
our series, 3 out of 13 patients with FS-DFSP and wide
margins developed distant relapse. We believe that an
higher rate of local and distant recurrence in FS-DFSP
compared to DFSP could be related to the presence of
high-grade fibrosarcomatous changes and not only to the
status of margins. The different results from our and
Goldblum studies may be due to differences in patient
selection.
Apo-D and CD34 were recently employed as useful
markers in differentiating superficial tumors, including
DFSP [22]. In our series, the positivity to both mem-
brane markers was documented in about 2/3 of patients.
The expression is lower in FS-DFSP compared with
DFSP. EFS at 5 years was significantly better in CD34
positive patients. Very similarly, Apo-D positive patients,
had an EFS at 5 years of 73%, compared to 33% in Apo-
D negative cases. We did not find significant differences
according to histology (DFSP vs. FS-DFSP), site or mar-
gins in the 2 groups. The multivariate analysis did not
confirm the independent prognostic significance of the
expression of Apo-D and CD34, possibly because of the
Figure 1 Histology. Bland appearing spindle cells arranged in monotonous storiform pattern, infiltrating between lobules of fat in an
honeycomb pattern in DFSP (H&E; panel a). CD34 (panel b) and Apolipoprotein-D (panel c) expression in DFSP. Malignat fibrous histicitoma-like
areas in DFSP (DFSP-FS) (panel d). Loss of expression of CD 34 (panel e) and Apolopoprotein-D (panel f).
Table 2 Immunoistochemical Expression of CD34 and
Apolipoprotein D*
All (26
pts)
DFSP (15
pts)
FS-DFSP (11
pts)
n (%) n (%) n (%)
CD34
Yes 20 (77) 13 (87) 7 (63) p =
0.3
No 6 (23) 2 (13) 4 (37)
Apolipoprotein-
D
Yes 17 (65) 11 (73) 6 (55) p =
0.4
No 9 (35) 4 (27) 5 (45)
* in 26 patients; pts: patients; DFSP: dermatofibrosaroma protuberans; FS-DFSP
fibrosarcomatous-DFSP
Palmerini et al. Clinical Sarcoma Research 2012, 2:4
http://www.clinicalsarcomaresearch.com/content/2/1/4
Page 4 of 6small sample size. To our knowledge, our series is the
first addressing their prognostic role in the subset of
DFSP or FS-DFSP. Our observation, an increased risk of
local recurrence in patients with lower expression of
these markers, should be considered in the planning of
the surgical strategy.
Conclusions
Patients with DFSP have a high survival probability. In
this series, limb location, inadequate surgical margins
and fibrosarcomatous changes were associated with
higher local and metastatic recurrence. The role of adju-
vant therapies has yet to be defined. Loss of CD34+
Figure 2 Overall Survival. Five-year overall survival (OS) in 40 DFSP patients with localized disease and metastatic disease at presentation (left).
Five-year overall survival (OS) according to histology (right).
Figure 3 Five-year event free survival (EFS) according to histology, adequacy of surgical margins and site.
Figure 4 Five-year event free survival (EFS) according to CD34 and Apolipoprotein-D expression.
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a worse prognosis in this series.
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Table 3 Local and distant recurrence rate in FS-DFSP
Ref. Pts n° Distant Local
Palmerini et al., current study 13 23% 42%
Mentzel T et al., AJSP 1998 [6] 41 15% 58%
Bowne WB et al., Cancer 2000 [15] 25 8% 52%
Fiore M et al, JCO 2005 [16] 7 28% 28%
Abbott JJ et al. AJSP 2006 [17] 41 10% 20%
Goldblum JR et al., AJSP 2000 [18] 18 0% 22%
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